TRIAL INFORMATION
Sponsor:NeuroPath Biosciences
Therapeutic Area:Neurology
Phase:PHASE III
Indication:Parkinsons Disease
Target Enrollment:35 patients
Est. Duration:36 months
SITE INFORMATION
Site:MedPoint Clinical Research - Nashville
Principal Investigator:Dr. Sarah Chen, MD, PhD
Total FTE Capacity:12
Available FTE:1.8
Active Trials:6
Completed Trials:18
Pool Analysis
FTE Analysis
Financial
Risk Assessment
Recommendation
Patient Pool Adequacy Analysis
Assessing whether the available patient pool can support target enrollment
A pool adequacy ratio of 2.5x or higher indicates comfortable capacity for successful enrollment.
TOTAL POOL
1,800
AVAILABLE
1,480
320 allocated
REQUIRED
35
ADEQUACY RATIO
42.3x
Pool Utilization
Current Allocation17.8%
If This Trial Accepted19.7%
Pool is Sufficient
Available pool is 42.3x the target enrollment, providing a comfortable buffer for recruitment.
Pool Adequacy Score100 / 100